Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy
- PMID: 37646021
- PMCID: PMC10461088
- DOI: 10.3389/fimmu.2023.1195194
Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy
Abstract
Hematological malignancy is a disease arisen by complicate reasons that seriously endangers human health. The research on its pathogenesis and therapies depends on the usage of animal models. Conventional animal model cannot faithfully mirror some characteristics of human features due to the evolutionary divergence, whereas the mouse models hosting human hematological malignancy are more and more applied in basic as well as translational investigations in recent years. According to the construction methods, they can be divided into different types (e.g. cell-derived xenograft (CDX) and patient-derived xenograft model (PDX) model) that have diverse characteristics and application values. In addition, a variety of strategies have been developed to improve human hematological malignant cell engraftment and differentiation in vivo. Moreover, the humanized mouse model with both functional human immune system and autologous human hematological malignancy provides a unique tool for the evaluation of the efficacy of novel immunotherapeutic drugs/approaches. Herein, we first review the evolution of the mouse model of human hematological malignancy; Then, we analyze the characteristics of different types of models and summarize the ways to improve the models; Finally, the way and value of humanized mouse model of human immune system in the immunotherapy of human hematological malignancy are discussed.
Keywords: PDX model; hematological malignancy; humanized mice; immune system; immune therapy.
Copyright © 2023 Lang, Lyu, Tan and Hu.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes.Front Immunol. 2021 Mar 29;12:607282. doi: 10.3389/fimmu.2021.607282. eCollection 2021. Front Immunol. 2021. PMID: 33854497 Free PMC article.
-
Humanized mouse models of genetic immune disorders and hematological malignancies.Biochem Pharmacol. 2020 Apr;174:113671. doi: 10.1016/j.bcp.2019.113671. Epub 2019 Oct 18. Biochem Pharmacol. 2020. PMID: 31634456 Free PMC article. Review.
-
Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.MAbs. 2018 Nov-Dec;10(8):1301-1311. doi: 10.1080/19420862.2018.1518948. Epub 2018 Oct 2. MAbs. 2018. PMID: 30204048 Free PMC article.
-
Construction of a Humanized PBMC-PDX Model to Study the Efficacy of a Bacterial Marker in Lung Cancer Immunotherapy.Dis Markers. 2022 Aug 28;2022:1479246. doi: 10.1155/2022/1479246. eCollection 2022. Dis Markers. 2022. PMID: 36072895 Free PMC article.
-
Humanized mice are precious tools for evaluation of hematopoietic gene therapies and preclinical modeling to move towards a clinical trial.Biochem Pharmacol. 2020 Apr;174:113711. doi: 10.1016/j.bcp.2019.113711. Epub 2019 Nov 11. Biochem Pharmacol. 2020. PMID: 31726047 Review.
Cited by
-
Experimental Cell Models for Investigating Neurodegenerative Diseases.Int J Mol Sci. 2024 Sep 9;25(17):9747. doi: 10.3390/ijms25179747. Int J Mol Sci. 2024. PMID: 39273694 Free PMC article. Review.
-
Development of bispecific T cell engagers: harnessing quantitative systems pharmacology.Trends Pharmacol Sci. 2023 Dec;44(12):880-890. doi: 10.1016/j.tips.2023.09.009. Epub 2023 Oct 17. Trends Pharmacol Sci. 2023. PMID: 37852906 Free PMC article. Review.
-
Lymph Node-on-Chip Technology: Cutting-Edge Advances in Immune Microenvironment Simulation.Pharmaceutics. 2024 May 16;16(5):666. doi: 10.3390/pharmaceutics16050666. Pharmaceutics. 2024. PMID: 38794327 Free PMC article. Review.
-
Development of iPSC-derived human bone marrow organoid for autonomous hematopoiesis and patient-derived HSPC engraftment.Blood Adv. 2025 Jan 14;9(1):54-65. doi: 10.1182/bloodadvances.2024013361. Blood Adv. 2025. PMID: 39471483 Free PMC article.
-
Modeling mesenchymal stromal cell support to hematopoiesis within a novel 3D artificial marrow organoid system.Sci Rep. 2025 Jul 2;15(1):23603. doi: 10.1038/s41598-025-07717-9. Sci Rep. 2025. PMID: 40604201 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources